The 9th edition of Pharmalytics is now available exclusively to Pharma.Aero members, bringing together expert perspectives, market intelligence and key developments in pharmaceutical and life sciences logistics during Q3 2026.
The geography of the pharmaceutical industry is changing, and so are the demands placed on its supply chains. Shifting trade flows, geopolitical tensions, regional dependencies and the growing role of Asian markets are challenging established approaches to pharmaceutical logistics.
In this edition, Pharmalytics examines how these developments are influencing the industry, from the concentration of upstream supply chains to the changing geography of clinical research and medical device development.
Q3 2026 – Key Insights & Expert Perspectives
Editorial Column: The New Paradox of Pharma Globalisation, by Wouter Dewulf – Antwerp Management School
Pharma market data: Pharmalogistics in an age of dependency, disruption and geopolitics – How upstream concentration, policy divergence and changing trade flows are moving pharma logistics from cost efficiency toward strategic optionality.
Pharma development: The map of pharma is moving. Is the supply chain moving with it? How China and India are accelerating clinical research, medical device development and redesigning the healthcare trial landscape
Logistics Markets Q3 2026: Local Mergers, Global Investments and Geopolitical Shifts – The most strategically significant developments of the quarter
Accessing the Report
The Pharmalytics reports are available exclusively to Pharma.Aero members via the secure members’ area. This public article serves as an overview only. Detailed data, analysis, and insights remain confidential.